KR980002019A - 오르토-치환된 벤조일구아니딘, 이의 제법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제 - Google Patents
오르토-치환된 벤조일구아니딘, 이의 제법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제 Download PDFInfo
- Publication number
- KR980002019A KR980002019A KR1019970022785A KR19970022785A KR980002019A KR 980002019 A KR980002019 A KR 980002019A KR 1019970022785 A KR1019970022785 A KR 1019970022785A KR 19970022785 A KR19970022785 A KR 19970022785A KR 980002019 A KR980002019 A KR 980002019A
- Authority
- KR
- South Korea
- Prior art keywords
- carbon atoms
- alkyl
- compound
- cycloalkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- AJDQRQQNNLZLPM-UHFFFAOYSA-N n-(diaminomethylidene)benzamide Chemical class NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 title claims 14
- 239000000032 diagnostic agent Substances 0.000 title 1
- 229940039227 diagnostic agent Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 claims abstract 7
- 230000000302 ischemic effect Effects 0.000 claims abstract 4
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract 2
- 206010003119 arrhythmia Diseases 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- -1 biphenylyl Chemical group 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 238000004519 manufacturing process Methods 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000023589 ischemic disease Diseases 0.000 claims 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000005493 quinolyl group Chemical group 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 abstract 2
- 230000007574 infarction Effects 0.000 abstract 2
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000003293 cardioprotective effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000035778 pathophysiological process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19622370A DE19622370A1 (de) | 1996-06-04 | 1996-06-04 | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19622370.9 | 1996-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR980002019A true KR980002019A (ko) | 1998-03-30 |
Family
ID=7796095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970022785A Ceased KR980002019A (ko) | 1996-06-04 | 1997-06-03 | 오르토-치환된 벤조일구아니딘, 이의 제법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6011063A (enExample) |
| EP (1) | EP0811610B1 (enExample) |
| JP (1) | JP4101904B2 (enExample) |
| KR (1) | KR980002019A (enExample) |
| CN (1) | CN1064956C (enExample) |
| AR (1) | AR008761A1 (enExample) |
| AT (1) | ATE209630T1 (enExample) |
| AU (1) | AU723665B2 (enExample) |
| BR (1) | BR9703440A (enExample) |
| CA (1) | CA2206758C (enExample) |
| CZ (1) | CZ289411B6 (enExample) |
| DE (2) | DE19622370A1 (enExample) |
| DK (1) | DK0811610T3 (enExample) |
| ES (1) | ES2166487T3 (enExample) |
| HR (1) | HRP970304B1 (enExample) |
| HU (1) | HUP9700989A3 (enExample) |
| ID (1) | ID17038A (enExample) |
| IL (1) | IL120988A0 (enExample) |
| MX (1) | MX9704094A (enExample) |
| NO (1) | NO310188B1 (enExample) |
| NZ (1) | NZ314973A (enExample) |
| PL (1) | PL185757B1 (enExample) |
| PT (1) | PT811610E (enExample) |
| RU (1) | RU2214397C2 (enExample) |
| SI (1) | SI0811610T1 (enExample) |
| SK (1) | SK282628B6 (enExample) |
| TR (1) | TR199700453A2 (enExample) |
| TW (1) | TW429243B (enExample) |
| ZA (1) | ZA974869B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| US6639077B2 (en) | 2000-03-23 | 2003-10-28 | Merck Frosst Canada & Co. | Tri-aryl-substituted-ethane PDE4 inhibitors |
| MY123585A (en) | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
| JP2003534328A (ja) | 2000-05-25 | 2003-11-18 | メルク フロスト カナダ アンド カンパニー | フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤 |
| US6740666B2 (en) | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| WO2002094823A1 (en) | 2001-05-24 | 2002-11-28 | Merck Frosst Canada & Co. | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| WO2003077918A1 (en) | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| GB0916163D0 (en) * | 2009-09-15 | 2009-10-28 | Shire Llc | Prodrugs of guanfacine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ284456B6 (cs) * | 1992-02-15 | 1998-12-16 | Hoechst Aktiengesellschaft | Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje |
| EP0612723B1 (de) * | 1993-02-20 | 1997-08-27 | Hoechst Aktiengesellschaft | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament |
| DE4318756A1 (de) * | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4327244A1 (de) * | 1993-08-13 | 1995-02-16 | Hoechst Ag | Harnstoffsubstituierte Benzoylguandine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4328869A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4422685A1 (de) * | 1994-06-29 | 1996-01-04 | Hoechst Ag | Ortho-amino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
1996
- 1996-06-04 DE DE19622370A patent/DE19622370A1/de not_active Withdrawn
-
1997
- 1997-05-22 EP EP97108258A patent/EP0811610B1/de not_active Expired - Lifetime
- 1997-05-22 ES ES97108258T patent/ES2166487T3/es not_active Expired - Lifetime
- 1997-05-22 DE DE59705495T patent/DE59705495D1/de not_active Expired - Lifetime
- 1997-05-22 DK DK97108258T patent/DK0811610T3/da active
- 1997-05-22 AT AT97108258T patent/ATE209630T1/de not_active IP Right Cessation
- 1997-05-22 SI SI9730284T patent/SI0811610T1/xx unknown
- 1997-05-22 PT PT97108258T patent/PT811610E/pt unknown
- 1997-05-30 NZ NZ314973A patent/NZ314973A/en unknown
- 1997-06-02 ID IDP971869A patent/ID17038A/id unknown
- 1997-06-02 AU AU24650/97A patent/AU723665B2/en not_active Ceased
- 1997-06-02 AR ARP970102385A patent/AR008761A1/es unknown
- 1997-06-02 TW TW086107502A patent/TW429243B/zh active
- 1997-06-02 TR TR97/00453A patent/TR199700453A2/xx unknown
- 1997-06-02 SK SK696-97A patent/SK282628B6/sk unknown
- 1997-06-02 CN CN971054797A patent/CN1064956C/zh not_active Expired - Fee Related
- 1997-06-02 CZ CZ19971696A patent/CZ289411B6/cs not_active IP Right Cessation
- 1997-06-03 KR KR1019970022785A patent/KR980002019A/ko not_active Ceased
- 1997-06-03 HU HU9700989A patent/HUP9700989A3/hu unknown
- 1997-06-03 MX MX9704094A patent/MX9704094A/es unknown
- 1997-06-03 US US08/868,077 patent/US6011063A/en not_active Expired - Lifetime
- 1997-06-03 PL PL97320327A patent/PL185757B1/pl not_active IP Right Cessation
- 1997-06-03 NO NO19972527A patent/NO310188B1/no not_active IP Right Cessation
- 1997-06-03 ZA ZA9704869A patent/ZA974869B/xx unknown
- 1997-06-03 JP JP14439397A patent/JP4101904B2/ja not_active Expired - Fee Related
- 1997-06-03 HR HR970304A patent/HRP970304B1/xx not_active IP Right Cessation
- 1997-06-03 RU RU97109913/04A patent/RU2214397C2/ru not_active IP Right Cessation
- 1997-06-03 IL IL12098897A patent/IL120988A0/xx unknown
- 1997-06-04 CA CA002206758A patent/CA2206758C/en not_active Expired - Fee Related
- 1997-06-04 BR BR9703440A patent/BR9703440A/pt not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100275603B1 (ko) | 아미노-치환된 벤조일구아니딘, 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
| KR950022159A (ko) | 치환된 1-옥소-1,2-디하이드로이소퀴놀리노일구아니딘 및 1,1-디옥소-2h-1,2-벤조티아지노일구아니딘, 이들의 제조방법, 약제 또는 진단제로서의 이들의 용도 및 이들을 포함하는 약제 | |
| US5929093A (en) | Bifunctional acetylcholinesterase reactivators | |
| KR970025611A (ko) | 치환된 설폰이미다미드, 이의 제조방법,약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 | |
| JP3875731B2 (ja) | ３，５−置換されたアミノベンゾイルグアニジン、それらの製法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬 | |
| KR980002019A (ko) | 오르토-치환된 벤조일구아니딘, 이의 제법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제 | |
| JPH06234727A (ja) | 置換されたベンゾイルグアニジン、それらの製法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬 | |
| KR950032129A (ko) | 치환된 비사이클릭의 헤테로아로일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 | |
| KR960010619A (ko) | 헤테로사이클릭 n-옥사이드에 의해 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도, 이를 함유하는 약제 및 이의 제조를 위한 중간 생성물 | |
| KR970074776A (ko) | 치환된 2-나프토일구아니딘, 이의 제조방법, 약물 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 | |
| KR970006282A (ko) | 4-플루오로알킬-치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도, 및 이를 포함하는 약제 | |
| KR970015568A (ko) | 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제 | |
| RU97109913A (ru) | Орто-замещенные бензоилгуанидины, способ их получения, их применение в качестве медикамента или диагностического средства и содержащий их медикамент | |
| JPH1067731A5 (enExample) | ||
| KR970026597A (ko) | 설포닐아미노-치환된 벤조일구아니딘, 이의 제조 방법, 약제 또는 진단 보조제로서의 이의 용도 및 이를 함유하는 약제 | |
| RU95115408A (ru) | Замещенные бензоилгуанидины, способ их получения, содержащее их лекарственное средство, способ или средства его получения, способ лечения | |
| KR960010620A (ko) | 플루오로알킬/알케닐-치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 | |
| KR970065512A (ko) | 오르토-치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도, 및 이를 포함하는 약제 | |
| TW445261B (en) | A substituted thiophenylalkenylcarboxylic acid guanidide compound having the cellular Na<SP>+</SP>/H<SP>+</SP> exchanger inhibitory activity, the preparation processes and the pharmaceutical compositions thereof | |
| KR100498799B1 (ko) | 오르토-치환된벤조일구아니딘,이의제조방법및이를포함하는약제학적조성물 | |
| KR970065511A (ko) | 오르토-치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제 | |
| KR960017628A (ko) | 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 | |
| RU97103361A (ru) | Орто-замещенные бензоилгуанидины, способ их получения, их применение в качестве медикамента или диагностического средства и содержащий их медикамент | |
| KR970061861A (ko) | 오르토 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이 용도 및 이를 함유하는 약제 | |
| KR970074756A (ko) | 비스-오르토-치환된 벤조일구아니딘, 이의 제조 방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19970603 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20020531 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19970603 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20041030 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20050228 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20041030 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |